Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759385 | 0.81 | CA12 (0.34) | CA12CA2CA14L3MBTL1PTPRC | |
| SCHEMBL6096929 | 0.78 | CA12 (0.33) | CA12CA2CA14PTPRCCYP2D6 | |
| SCHEMBL6937980 | 0.77 | MEN1 (0.40) | CA12CA2CA14L3MBTL1PTPRC | |
| SCHEMBL756932 | 0.77 | CA2 (0.39) | CA12CA2CA14L3MBTL1PTPRC | |
| SCHEMBL6094410 | 0.75 | PTPRC (0.33) | CA12CA2CA14PTPRC | |
| SCHEMBL22367564 | 0.74 | TDP1 (0.38) | CA12CA2CA14L3MBTL1PTPRC | |
| SCHEMBL1278083 | 0.74 | CA12 (0.35) | CA12CA2CA14L3MBTL1PTPRC | |
| SCHEMBL22034469 | 0.74 | TDP1 (0.54) | CA12CA2MEN1GAAKMT2A | |
| SCHEMBL6095955 | 0.74 | PTPRC (0.32) | CA12CA2CA14PTPRC | |
| SCHEMBL21564883 | 0.72 | CA2 (0.36) | CA12CA2CA14L3MBTL1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109352-B2 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6720449-B2 | N-PROTECTING AN OPTICALLY ACTIVE 3-HALOALANINE DERIVATIVE FOLLOWED BY CYCLIZATION FOR AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030032814-A1 | Process for preparing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1179530-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE AMINO ACID DERIVATIVES | Kaneka Corporation (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | NPEPPS, AAAS, DDC | CA12 1984/4885CA2 286/4885CA14 2621/4885 |
| US-20030032814-A1 | Process for preparing optically active amino acid derivatives | NPEPPS, AAAS, DDC | CA12 2363/4885CA2 398/4885CA14 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.